



NUTRITION UNIT

SCIENTIFIC PANEL ON NUTRITION, NOVEL FOODS AND FOOD ALLERGENS

MINUTES OF THE 107TH PLENARY MEETING

**Held on 22 October 2020 via web conference
(Agreed on 30 October 2020)**

Participants

■ Panel Members:

Jacqueline Castenmiller, Stefaan de Henauw, Karen Ildico Hirsch-Ernst, John Kearney, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J. McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Dominique Turck (Chair) and Marco Vinceti.

■ Hearing Experts:

Not Applicable

■ European Commission:

Takis Daskaleros

■ EFSA:

NUTRI Unit: Paolo Colombo, Valeriu Curtui, Agnès Desesmaisons-Lecarré, Céline Dumas, Andrea Germini, Leng Heng, Ariane Titz and Silvia Valtueña Martínez

AMU Unit: Laura Ciccolallo and Laura Martino (for agenda item 8.1)

COM Team: Anthony Smith (for agenda item 8.2)

■ Others:

Not Applicable



1. Welcome and apologies for absence

The Chair welcomed the participants. No apologies were received.

2. Adoption of agenda

The agenda was adopted without changes.

3. Declarations of Interest of Scientific Panel members

In accordance with EFSA's Policy on Independence¹ and the Decision of the Executive Director on Competing Interest Management², EFSA screened the Annual Declarations of Interest filled out by the Panel members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

4. The minutes of the 106th Plenary meeting held on 22-23 September 2020

The **minutes** of the 106th Plenary meeting held on 22-23 September 2020 were agreed by written procedure on 29 September 2020.

5. Scientific outputs submitted for discussion and/or possible adoption

5.1 **Draft opinion on the Nutritional safety and suitability of a specific protein hydrolysate derived from whey protein concentrate and used in an infant and follow-on formula manufactured from hydrolysed protein – Applicant: DANONE Trading ELN B.V. (EFSA-Q-2019-00652)**

The draft opinion was presented. The Panel reviewed and discussed the sections regarding the characterisation of the protein hydrolysate, the characterisation of the formula manufactured from this hydrolysate and used in the clinical studies provided, and the human intervention studies submitted to support the nutritional safety and suitability of the protein hydrolysate. The opinion was adopted by the Panel on 22 October subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6304>

5.2 **Draft opinion on the Safety of lacto-N-neotetraose produced by derivative strains of E.coli BL21 as a novel food (NF 2019/1152) – Applicant: Jennewein Biotechnologie GmbH (EFSA-Q-2019-00448)**

The draft opinion was presented. The Panel reviewed and discussed the sections regarding composition, production process, specifications, proposed uses and use levels, anticipated daily intake, nutritional information and allergenicity of the Novel Food. The opinion was adopted by the Panel on 22 October subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6305>

¹ http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf

² http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf



6. New mandates

Postponed

7. Feedback from the Scientific Committee/Scientific Panels, EFSA, the European Commission

Postponed

8. Other scientific topics for information and/or discussion

8.1 Draft Scientific opinion on the Tolerable Upper Intake Level of dietary sugars (EFSA-Q-2016-00414)

The Panel re-discussed the principles developed for evidence integration and uncertainty analysis in relation to metabolic disease endpoints and agreed on the approach.

8.2 EFSA Guidance on Communication of Uncertainty (EFSA-Q-2017-00466)

The Panel was given an outline of EFSA guidance on how to report and communicate the various expressions of uncertainty described in EFSA's scientific document to the target audience.

9. Any Other Business

The Panel took note of the following:

- With reference to the mandate received from EC asking EFSA to re-evaluate the safety in use of selenium (EFSA-Q-2020-00618), there was a need for setting up a new working group (WG) on tolerable intake upper levels (ULs) for vitamins and minerals. Androniki Naska has been appointed as the chair of the WG. The full composition of the WG, once established, will be published on the EFSA website.
- The Panel was informed about the first meeting of the International Liaison Group (ILG) on nutrient reference values (NRVs) methodologies which took place on the 7th of October. It gathered representatives of authoritative bodies in charge of NRVs at regional or global level (US FDA, Health Canada, Australian Ministry of Health, New Zealand Ministry of Primary Industries, FAO and WHO). The objectives of the ILG are i) to exchange information on ongoing activities related to reference values, ii) to share experience on methodological approaches for establishing reference values, iii) to identify potential areas of international collaboration, in particular regarding conceptual and methodological developments, and, ultimately, iv) to foster global harmonization in this field. The terms of reference of the ILG were agreed and topics and activities of common interest were explored. This included sharing views and experiences regarding the application of GRADE and GRADE-like approaches to NRVs setting and the integration of chronic disease endpoints into the NRVs framework.
- The Panel was informed that the drafting group on the assessment of additional scientific evidence in relation to the Scientific Opinion on the Essential Composition of Total Diet Replacement for Weight Control has held two meetings on 14 September and 19 October, respectively, in which the draft protocol was discussed.



- The next plenary meetings of the NDA Panel for 2020 are scheduled via web conference:
 - 24-26 November 2020. The session on 26 November will be open to observers.
 - 16-17 December 2020